WO2022268115A1 - 拟穴青蟹抗菌多肽Spampcin 56-86及其应用 - Google Patents

拟穴青蟹抗菌多肽Spampcin 56-86及其应用 Download PDF

Info

Publication number
WO2022268115A1
WO2022268115A1 PCT/CN2022/100406 CN2022100406W WO2022268115A1 WO 2022268115 A1 WO2022268115 A1 WO 2022268115A1 CN 2022100406 W CN2022100406 W CN 2022100406W WO 2022268115 A1 WO2022268115 A1 WO 2022268115A1
Authority
WO
WIPO (PCT)
Prior art keywords
spampcin
scylla
antibacterial
polypeptide
drug
Prior art date
Application number
PCT/CN2022/100406
Other languages
English (en)
French (fr)
Inventor
王克坚
江曼玉
陈芳奕
Original Assignee
厦门大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 厦门大学 filed Critical 厦门大学
Publication of WO2022268115A1 publication Critical patent/WO2022268115A1/zh
Priority to US18/454,855 priority Critical patent/US20230404076A1/en

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N37/00Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
    • A01N37/44Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio analogue, or a derivative thereof, and a nitrogen atom attached to the same carbon skeleton by a single or double bond, this nitrogen atom not being a member of a derivative or of a thio analogue of a carboxylic group, e.g. amino-carboxylic acids
    • A01N37/46N-acyl derivatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43509Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from crustaceans
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01PBIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS
    • A01P1/00Disinfectants; Antimicrobial compounds or mixtures thereof
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01PBIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS
    • A01P3/00Fungicides
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K20/00Accessory food factors for animal feeding-stuffs
    • A23K20/10Organic substances
    • A23K20/142Amino acids; Derivatives thereof
    • A23K20/147Polymeric derivatives, e.g. peptides or proteins
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K20/00Accessory food factors for animal feeding-stuffs
    • A23K20/10Organic substances
    • A23K20/195Antibiotics
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K50/00Feeding-stuffs specially adapted for particular animals
    • A23K50/70Feeding-stuffs specially adapted for particular animals for birds
    • A23K50/75Feeding-stuffs specially adapted for particular animals for birds for poultry
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K50/00Feeding-stuffs specially adapted for particular animals
    • A23K50/80Feeding-stuffs specially adapted for particular animals for aquatic animals, e.g. fish, crustaceans or molluscs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the invention belongs to the technical field of marine molecular biology, and in particular relates to an antibacterial polypeptide Spampcin 56-86 of Scylla pseudocaveus and its application.
  • Antibacterial peptides are a class of small-molecule antimicrobial peptides that are widely distributed in animals and plants. They serve as the first line of defense against infection by various pathogenic microorganisms and are an important part of the innate immune system. The main mechanism of disease resistance is to act on the cell membrane of pathogenic microorganisms, making it difficult for pathogenic microorganisms to develop resistance to them, thus avoiding the problem of drug resistance and having broad-spectrum antibacterial, antifungal, antiviral, antiparasitic and other activities .
  • antimicrobial peptides also have multiple roles such as immunomodulators, signaling molecules, and anti-tumors, making them attractive alternatives to traditional antibiotics and important candidates for the development of new antibacterial drugs, and they also have considerable potential in transformation applications. prospect.
  • Antimicrobial peptides are divided into ⁇ -antimicrobial peptides, ⁇ -antimicrobial peptides and extended cyclic antimicrobial peptides according to their secondary structures; they are divided into cationic antimicrobial peptides and anionic antimicrobial peptides according to the number of charges they carry.
  • the antimicrobial peptide (CAMPR3) database has collected 10,247 natural and synthetic peptides, and a variety of antimicrobial peptides with broad-spectrum antimicrobial activity have also been found from marine animals, such as Crustins, ALFs, and Penaeidins in the hemolymph of prawns.
  • the purpose of the present invention is to provide an antibacterial polypeptide Spampcin 56-86 of Scylla pseudocarpus.
  • Another object of the present invention is to provide the application of the above-mentioned Scylla pseudophylla antibacterial polypeptide Spampcin 56-86 .
  • An antimicrobial peptide of Scylla sclerophyllum, Spampcin 56-86 has a molecular formula of C 227 H 373 N 71 O 62 S 1 , and its amino acid sequence is shown in SEQ ID NO: 01.
  • the second technical scheme of the present invention is as follows:
  • the antibacterial drugs are effective against Staphylococcus aureus and its drug-resistant bacteria, Listeria, Enterococcus faecalis, Enterococcus faecium, Staphylococcus epidermidis , Pseudomonas aeruginosa, Acinetobacter baumannii and its drug-resistant bacteria, Aeromonas sobria, Aeromonas hydrophila, Escherichia coli and its drug-resistant bacteria, Edwardsiella tarda and Pseudomonas fluorescens Bacteria have inhibitory and killing effects.
  • the third technical scheme of the present invention is as follows:
  • An antibacterial drug the active ingredient of which includes the above-mentioned Scylla antibacterial polypeptide Spampcin 56-86 .
  • its active ingredient is the above-mentioned Scylla syringae antibacterial polypeptide Spampcin 56-86 .
  • a preparation of antifungal medicine the active ingredient of which includes the above-mentioned antibacterial polypeptide Spampcin 56-86 of Scylla syringae.
  • its active ingredient is the above-mentioned Scylla syringae antibacterial polypeptide Spampcin 56-86 .
  • An aquatic feed additive the active ingredient of which includes the above-mentioned mud crab antibacterial polypeptide Spampcin 56-86 .
  • its active ingredient is the above-mentioned Scylla syringae antibacterial polypeptide Spampcin 56-86 .
  • the antimicrobial peptide Spampcin 56-86 of the mud crab of the present invention consists of 31 amino acids, the molecular formula is C 154 H 256 N 54 O 33 S 3 , the molecular weight is 3488.25 Daltons, and it contains 7 positively charged amino acids residues and 0 negatively charged amino acid residues, the isoelectric point of the antimicrobial peptide is predicted to be 11.71 according to the charge of the amino acid residues, and the average coefficient of hydrophilicity is -0.410, which is a cationic polypeptide with a positive charge.
  • the antimicrobial peptide Spampcin 56-86 of the mud crab of the present invention has significant antibacterial effects on Gram-positive bacteria, Gram-negative bacteria and molds.
  • Spampcin 56-86 has a significant antibacterial effect on normal mud crab blood cells, Normal mammalian cells such as mouse liver parenchymal cells and human normal liver cells do not have cytotoxic effects.
  • the antibacterial peptide Spampcin 56-86 of the mud crab of the present invention has strong antibacterial activity and antifungal activity, good antibacterial effect, wide antibacterial spectrum, and fast bactericidal rate, and can be developed into antibacterial drugs and antifungal drugs , and can be applied to aquatic feed additives, and has broad application prospects.
  • Fig. 1 is the sterilizing kinetics diagram of Scylla pseudophylla antibacterial polypeptide Spampcin 56-86 to Staphylococcus aureus, Pseudomonas aeruginosa, Aeromonas hydrophila, Escherichia coli in the embodiment of the present invention 3; Wherein , the abscissa is the time (min), and the ordinate is the bactericidal index (%).
  • Fig. 2 is antimicrobial thermostability figure of Staphylococcus aureus, Pseudomonas aeruginosa antimicrobial peptide Spampcin 56-86 in the embodiment of the present invention 4 in the crab crab; Wherein, abscissa is time (h), and ordinate is OD 600 values.
  • Fig. 3 is the experimental diagram of inhibition of Fusarium graminearum spore germination by the antimicrobial polypeptide Spampcin 56-86 of Scylla pseudocarpus in Example 5 of the present invention; wherein, the concentration of the antibacterial polypeptide Spampcin 56-86 of Scylla pseudocarpus is: A: 0 ⁇ M, B : 6 ⁇ M, C: 12 ⁇ M;
  • Fig. 4 is an experimental diagram of the inhibition of Fusarium oxysporum spore germination by the antibacterial polypeptide Spampcin 56-86 of the mud crab in Example 5 of the present invention; wherein, the concentration of the antibacterial polypeptide Spampcin 56-86 of the mud crab is: A: 0 ⁇ M, B : 6 ⁇ M, C: 12 ⁇ M;
  • Fig. 5 is a scanning electron microscope observation image of the antibacterial peptide Spampcin 56-86 of Scylla pseudocarpus in Example 6 of the present invention interacted with Staphylococcus aureus; wherein, A: Staphylococcus aureus, B: Staphylococcus aureus + 12 ⁇ M Spampcin 56-86 .
  • Fig. 6 is the scanning electron microscope observation picture after the antimicrobial polypeptide Spampcin 56-86 of Scylla pseudocaves in Example 6 of the present invention interacts with Pseudomonas aeruginosa; wherein, A: Pseudomonas aeruginosa, B: Pseudomonas aeruginosa + 12 ⁇ M Spampcin 56-86 .
  • Fig. 7 is an experiment diagram of the MTS-PMS method to detect the cytotoxicity of the antimicrobial polypeptide Spampcin 56-86 of Scylla mitae; wherein, the abscissa is the protein concentration of Spampcin 56-86 ( ⁇ M), and the ordinate is the cell proliferation rate (%).
  • the amino acid sequence of the Scylla pseudosyrpa antibacterial polypeptide Spampcin 56-86 is:
  • the antimicrobial peptide Spampcin 56-86 of Scylla pseudocarpa with a purity of more than 95% can be obtained by using the existing solid-phase chemical synthesis method.
  • GenScript (Jiangsu) Co., Ltd. was entrusted to GenScript (Jiangsu) Co., Ltd. to synthesize the antimicrobial polypeptide Spampcin 56-86 in this example by solid-phase synthesis, and provide detection information such as molecular weight of the polypeptide and HPLC.
  • the physical and chemical parameters of the antibacterial peptide Spampcin 56-86 of Scylla pseudocaveus are shown in Table 1:
  • Spampcin 56-86 has a small molecular weight and good stability, and is a positively charged cationic polypeptide.
  • Example 2 Determination of minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of the antibacterial polypeptide Spampcin 56-86 of Scylla pseudocaveus
  • the bacterial strains involved in this embodiment include: Staphylococcus aureus (Staphylococcusaureus), Staphylococcus epidermidis (Staphylococcus usepidermidis), Enterococcus faecium (Enterococcus faecium), Enterococcus faecalis (Enterococcus faecalis), Listeria monocytogenes (Listeriamonocytogenes), Escherichia coli Escherichia coli, Pseudomonas hydrophila, Aeromonas hydrophila, Aeromonas sobria, Edwardsiella tarda, Pseudomonas fluorescens , Acinetobacter baumannii, Staphylococcus aureus, Acinetobacter baumannii, Escherichia coli, Fusarium oxysporum ), Fusarium graminearum, Fusarium solani.
  • Aeromonas temperatus and Edwardsiella tarda were donated by Fujian Provincial Fisheries Research Institute, and clinical isolates of drug-resistant Staphylococcus aureus, drug-resistant Acinetobacter baumannii and drug-resistant Escherichia coli came from the affiliated Branch of Fujian Medical University The Laboratory Department of the Second Hospital, and the rest of the strains were purchased from the Culture Collection Center of the Institute of Microbiology, Chinese Academy of Sciences, and stored in this laboratory.
  • Blank control group 50 ⁇ L protein sample to be tested and 50 ⁇ L culture medium
  • Negative control group 50 ⁇ L sterile MilliQ water and 50 ⁇ L bacterial suspension
  • MIC minimum inhibitory concentration ( ⁇ M), represented by a-b.
  • a The highest protein concentration at which bacterial growth can be seen with naked eyes;
  • b The lowest protein concentration at which no bacterial growth can be seen with naked eyes.
  • MBC minimum bactericidal concentration ( ⁇ M), expressed by a-b. a: The highest protein concentration on the plate with visible colony growth; b: The lowest protein concentration on the plate without colony growth.
  • Staphylococcus aureus Pseudomonas aeruginosa, Aeromonas hydrophila and Escherichia coli were selected as the test bacteria to determine the bactericidal kinetics of the antibacterial polypeptide Spampcin 56-86 from Scylla syringae.
  • the specific method is similar to the antibacterial activity assay described in Example 2. Adjust the final concentration of the antibacterial peptide Spampcin 56-86 of Scylla to 1 times MBC (Staphylococcus aureus: 6 ⁇ M; Pseudomonas aeruginosa: 6 ⁇ M; Aeromonas hydrophila: 12 ⁇ M; Escherichia coli: 6 ⁇ M; ).
  • the bactericidal index refers to the ratio of the number of clones in the experimental group to be tested to the number of clones in the negative control group after co-incubation for a certain period of time, expressed as a percentage, and the results are shown in Figure 1.
  • Example 4 The antibacterial activity and thermal stability of the antibacterial polypeptide Spampcin 56-86 of Scylla pseudocaveus
  • Staphylococcus aureus and Pseudomonas aeruginosa were selected as the test bacteria to determine the thermal stability of the antibacterial activity of the antibacterial peptide Spampcin 56-86 from Scylla syringae.
  • the specific method is similar to the antibacterial activity assay described in Example 2. Adjust the final concentration of the antimicrobial peptide Spampcin 56-86 to 1 times MBC (Staphylococcus aureus: 6 ⁇ M, Pseudomonas aeruginosa: 6 ⁇ M), bathe in boiling water at 100 ° C for 10 min, 20 min, and 30 min, and then place on ice on standby. Spampcin 56-86 was co-incubated with the bacteria to be tested, and the OD 600 value was measured with a microplate reader at 0h, 12h, 24h, 36h, and 48h, and the results are shown in Figure 2.
  • Example 5 Microscopic observation of fungal spore germination after the action of the antibacterial polypeptide Spampcin 56-86 of Scylla pseudocaves
  • Fusarium oxysporum and Fusarium graminearum were selected as the tested bacteria to observe the effect of the antimicrobial peptide Spampcin 56-86 of Scylla pseudocarpus on the germination of mold spores.
  • the specific method is similar to the antibacterial activity assay described in Example 2. Adjust the protein concentration of the antimicrobial peptide Spampcin 56-86 of Scylla pseudocavena to 6 ⁇ M and 12 ⁇ M, and keep it on ice for later use; adjust the final concentration of each mold spore to 5 ⁇ 10 4 /mL. Mix equal volumes of various concentrations of Spampcin 56-86 and various mold spores in a 96-well cell culture plate, place them in a 28°C incubator, and culture them statically for 24 hours. Observe the germination of mold spores under an optical microscope. The results are shown in Figure 3 and Figure 4 shows.
  • Example 6 Scanning electron microscope observation of antibacterial polypeptide Spampcin 56-86 of Scylla pseudocaveus interacting with bacteria
  • the invention discloses an antimicrobial polypeptide Spampcin 56-86 of Scylla pseudocaveus and its application. Its molecular formula is C 154 H 256 N 54 O 33 S 3 , and its amino acid sequence is shown in SEQ ID NO: 01.
  • the antibacterial polypeptide of Scylla pseudocaveus Spampcin 56-86 of the present invention has strong antibacterial activity and antifungal activity, good antibacterial effect, wide antibacterial spectrum, and fast bactericidal rate. It can be developed into antibacterial drugs and antifungal drugs. It can be applied to aquatic feed additives, has broad application prospects, and has industrial practicability.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Husbandry (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Environmental Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Pest Control & Pesticides (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Insects & Arthropods (AREA)
  • Birds (AREA)
  • Medicinal Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Dentistry (AREA)
  • Agronomy & Crop Science (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)

Abstract

提供了一种拟穴青蟹抗菌多肽Spampcin 56-86,其氨基酸序列如SEQ ID NO:01所示。本发明的拟穴青蟹抗菌多肽Spampcin 56-86具有抗细菌及抗霉菌活性,抗菌谱广,既可用于研制抗细菌和抗霉菌药物,又可用于水产饲料添加剂。

Description

拟穴青蟹抗菌多肽Spampcin 56-86及其应用 技术领域
本发明属于海洋分子生物学技术领域,具体涉及一种拟穴青蟹抗菌多肽Spampcin 56-86及其应用。
背景技术
据报道,目前我国是全球最大的抗生素生产国和消费国,也是细菌耐药最严重的国家之一,抗生素大量不规范、不合理的使用引发一系列如:细菌耐药性增强、抑制动物免疫、影响人类健康以至破坏生态环境等问题。因此,开发新型高效的抗细菌药物,寻找抗生素有效的替代品成为亟待解决的问题。
抗菌肽(Antibacterialpeptides,AMPs)是一类小分子抗微生物多肽,广泛分布于动植物体内,作为第一道防线以抵御各类病原微生物的感染,是先天性免疫系统中的重要组成部分。主要的抗病机理是作用于病原微生物的细胞膜,使得病原微生物不易对其产生抗性,因而避免耐药性问题的产生且拥有广谱的抗细菌、抗霉菌、抗病毒、抗寄生虫等活性。此外抗菌肽还具备免疫调节剂、信号分子、抗肿瘤等多重角色使其成为极具吸引力的传统抗生素替代品和开发新型抗细菌药物的重要候选材料,并且在转化应用方面也具有相当大的前景。
根据二级结构不同将抗菌肽分为α-抗菌肽、β-抗菌肽和延伸环状抗菌肽;根据携带电荷数的不同将其分为阳离子抗菌肽和阴离子抗菌肽。截至目前,抗微生物肽(CAMPR3)数据库收集到10247条天然肽和合成肽,从海洋动物中也发现多种具有广谱抗微生物活性的抗菌肽,如Crustins、ALFs、在对虾血淋巴中的Penaeidins、源于组蛋白H2A的Sphistin、富含甘氨酸的新型抗菌肽Spgly-AMP以及从青蟹性腺中具有生殖免疫功能的scygonadin和SCY2等。海洋动物处于极端的海洋环境,缺乏获得性免疫,病原感染时主要依靠先天性免疫中的抗菌肽以及免疫效应因子的响应以对抗病原菌。近年来随着海洋生态环境的不断恶化,海水养殖病害频发的问题也日趋明显,因此,加速研发新型的抗菌多肽仍具有重要意义。
发明内容
本发明的目的在于提供一种拟穴青蟹抗菌多肽Spampcin 56-86
本发明的另一目的在于提供上述拟穴青蟹抗菌多肽Spampcin 56-86的应用。
本发明的技术方案之一如下:
一种拟穴青蟹抗菌多肽Spampcin 56-86,其分子式为C 227H 373N 71O 62S 1,其氨基酸序列如SEQ ID NO:01所示。
本发明的技术方案之二如下:
上述拟穴青蟹抗菌多肽Spampcin 56-86在制备抗细菌药物中的应用,该抗细菌药物对金黄色葡萄球菌及其耐药菌、李斯特菌、粪肠球菌、屎肠球菌、表皮葡萄球菌、铜绿假单胞菌、鲍曼不动杆菌及其耐药菌、温和气单胞菌、嗜水气单胞菌、大肠埃希氏菌及其耐药菌、迟缓爱德华氏菌和荧光假单胞菌具有抑制和杀灭作用。
本发明的技术方案之三如下:
一种抗细菌药物,其有效成分包括上述拟穴青蟹抗菌多肽Spampcin 56-86
在本发明的一个优选实施方案中,其有效成分为上述拟穴青蟹抗菌多肽Spampcin 56-86
本发明的技术方案之四如下:
上述拟穴青蟹抗菌多肽Spampcin56-86在制备防霉菌药物中的应用,该防霉菌药物对尖孢镰孢菌、禾谷镰孢菌和腐皮镰孢菌具有抑制和杀灭作用。
本发明的技术方案之五如下:
一种制备防霉菌药物,其有效成分包括上述拟穴青蟹抗菌多肽Spampcin 56-86
在本发明的一个优选实施方案中,其有效成分为上述拟穴青蟹抗菌多肽Spampcin 56-86
本发明的技术方案之六如下:
上述拟穴青蟹抗菌多肽Spampcin 56-86在制备水产饲料添加剂中的应用。
本发明的技术方案之七如下:
一种水产饲料添加剂,其有效成分包括上述拟穴青蟹抗菌多肽Spampcin 56-86
在本发明的一个优选实施方案中,其有效成分为上述拟穴青蟹抗菌多肽Spampcin 56-86
本发明的有益效果是:
1、本发明的拟穴青蟹抗菌多肽Spampcin 56-86由31个氨基酸组成,分子式为C 154H 256N 54O 33S 3,分子量为3488.25道尔顿,其中含有7个带正电的氨基酸残基和0个带负电的氨基酸残基,根据氨基酸残基电荷预测该抗菌肽等电点为11.71,亲水性平均系数为-0.410,是一种带有正电荷的阳离子多肽。
2、本发明的拟穴青蟹抗菌多肽Spampcin 56-86对革兰氏阳性菌、革兰氏阴性菌、霉菌均有显著的抗菌效果,此外,Spampcin 56-86对正常拟穴青蟹血细胞、正常哺乳动物细胞如小鼠肝实质细胞和人正常肝细胞不具有细胞毒性作用。
3、本发明的拟穴青蟹抗菌多肽Spampcin 56-86具有较强的抗细菌活性及抗霉菌活性,抗菌效果好,抗菌谱广,杀菌速率快,既可以研制成为抗细菌药物和抗霉菌药物,又可以应用于水产饲料添加剂,具有广泛的应用前景。
附图说明
图1为本发明实施例3中拟穴青蟹抗菌多肽Spampcin 56-86对金黄色葡萄球菌、铜绿假单胞菌、嗜水气单胞菌、大肠埃希氏菌的杀菌动力学图;其中,横坐标为时间(min),纵坐标为杀菌指数(%)。
图2为本发明实施例4中拟穴青蟹抗菌多肽Spampcin 56-86对金黄色葡萄球菌、铜绿假单胞菌抗菌热稳定性图;其中,横坐标为时间(h),纵坐标为OD 600值。
图3为本发明实施例5中拟穴青蟹抗菌多肽Spampcin 56-86抑制禾谷镰孢菌孢子萌发实验图;其中,拟穴青蟹抗菌多肽Spampcin 56-86浓度为:A:0μM,B:6μM,C:12μM;
图4为本发明实施例5中拟穴青蟹抗菌多肽Spampcin 56-86抑制尖孢镰孢菌孢子萌发实验图;其中,拟穴青蟹抗菌多肽Spampcin 56-86浓度为:A:0μM,B:6μM,C:12μM;
图5为本发明实施例6中拟穴青蟹抗菌多肽Spampcin 56-86与金黄色葡萄球菌作用后的扫描电镜观察图;其中,A:金黄色葡萄球菌,B:金黄色葡萄球菌+12μM Spampcin 56-86
图6为本发明实施例6中拟穴青蟹抗菌多肽Spampcin 56-86与铜绿假单胞菌作用后的扫描电镜观察图;其中,A:铜绿假单胞菌,B:铜绿假单胞菌+12μM Spampcin 56-86
图7为MTS-PMS法检测拟穴青蟹抗菌多肽Spampcin 56-86细胞毒性实验图;其中, 横坐标为Spampcin 56-86蛋白浓度(μM),纵坐标为细胞增殖率(%)。
具体实施方式
以下通过具体实施方式结合附图对本发明的技术方案进行进一步的说明和描述。
实施例1拟穴青蟹抗菌多肽Spampcin 56-86的制备
所述拟穴青蟹抗菌多肽Spampcin 56-86的氨基酸序列为:
Arg-Arg-Ala-Ala-His-Gly-Leu-Leu-Pro-Arg-Leu-Arg-Ala-Pro-Pro-Pro-Phe-His-Lys-Arg-Cys-Val-Cys-Leu-Cys-Arg-Thr-Ala-Pro-Pro-Pro(SEQ ID NO:01)
采用现有的固相化学合成的方法即可得到纯度达95%以上拟穴青蟹抗菌多肽Spampcin 56-86。本实施例中的拟穴青蟹抗菌多肽Spampcin 56-86委托金斯瑞(江苏)有限公司以固相合成方法合成获得并提供多肽分子量、HPLC等检测信息。拟穴青蟹抗菌多肽Spampcin 56-86理化参数如表1所示:
表1 拟穴青蟹抗菌多肽Spampcin 56-86理化参数
Figure PCTCN2022100406-appb-000001
由表1可知Spampcin 56-86分子量小、稳定性较好,是一种带有正电荷的阳离子多肽。
实施例2 拟穴青蟹抗菌多肽Spampcin 56-86最小抑菌浓度(MIC)和最小杀菌浓度(MBC)的测定
本实施例中所涉及到的菌株有:金黄色葡萄球菌(Staphylococcusaureus)、表皮 葡萄球菌(Staphylococcusepidermidis)、屎肠球菌(Enterococcusfaecium)、粪肠球菌(Enterococcusfaecalis)、李斯特菌(Listeriamonocytogenes)、大肠埃希氏菌(Escherichiacoli)、铜绿假单胞菌(Pseudomonashydrophila)、嗜水气单胞菌(Aeromonashydrophila)、温和气单胞菌(Aeromonassobria)、迟缓爱德华氏菌(Edwardsiellatarda)、荧光假单胞菌(Pseudomonasfluorescens)、鲍曼不动杆菌(Acinetobacterbaumannii)、耐药金黄色葡萄球菌(Staphylococcus aureus)、耐药鲍曼不动杆菌(Acinetobacterbaumannii)、耐药大肠埃希氏菌(Escherichiacoli)、尖孢镰孢菌(Fusariumoxysporum)、禾谷镰孢菌(Fusarium graminearum)、腐皮镰孢菌(Fusarium solani)。其中温和气单胞菌、迟缓爱德华氏菌来源福建省水产研究所赠送,临床分离菌株耐药金黄色葡萄球菌、耐药鲍曼不动杆菌及耐药大肠埃希氏菌来源福建医科大学附属第二医院检验科,其余菌株均购自中国科学院微生物研究所菌种保藏中心,由本实验室保种贮藏。
具体方法如下:
(1)将保种的金黄色葡萄球菌、表皮葡萄球菌、李斯特菌、屎肠球菌、粪肠球菌、大肠埃希氏菌、铜绿假单胞菌、嗜水气单胞菌、温和气单胞菌、迟缓爱德华氏菌、荧光假单胞菌、鲍曼不动杆菌、耐药金黄色葡萄球菌、耐药鲍曼不动杆和耐药大肠埃希氏菌涂布于营养肉汤平板上,在各适宜温度倒置培养18-24h;尖孢镰孢菌、禾谷镰孢菌、腐皮镰孢菌涂布于马铃薯葡萄糖平板上,于28℃倒置培养1-7d。
(2)从各平板上挑取菌落接种于相应的培养基斜面上,细菌继续培养18-24h,用10mM磷酸钠缓冲液(pH=7.4)将细菌从斜面上冲下,调整菌悬液浓度。用MH液体培养基和磷酸钠缓冲液混合液稀释细菌,使得菌体的最终浓度为3.3×10 4CFU/mL。用10mM磷酸钠缓冲液(pH=7.4)将霉菌孢子从斜面上冲下,用马铃薯葡萄糖液体培养基和磷酸钠缓冲液混合液稀释孢子,利用血球计数板在光学显微镜下对孢子计数,调整孢子浓度,使得霉菌孢子最终浓度为5×10 4个/mL。
(3)将已合成的拟穴青蟹抗菌多肽Spampcin 56-86粉末分别用灭菌MiliiQ水溶解,经过0.22μM滤膜过滤后,倍比稀释蛋白浓度至3μM、6μM、12μM、24μM、48μM、96μM,置于冰上备用。
(4)在96孔细胞培养板上,每种待测菌设置空白对照组、阴性对照组和待测实 验组,每组设置三个平行:
a空白对照组:50μL待测蛋白样品和50μL培养基
b阴性对照组:50μL无菌MilliQ水和50μL菌悬液
c待测实验组:50μL待测蛋白样品和50μL菌悬液
(5)将96孔细胞培养板置于28℃培养箱中,培养1-2d,观察待测实验组中MIC结果;将待测实验组吹打混匀后,吸取适量的菌液滴于相应固体培养基平板上,于适宜温度倒置培养1-2d,观察MBC结果。
拟穴青蟹抗菌多肽Spampcin 56-86的MIC、MBC观察结果如表2所示
表2拟穴青蟹抗菌多肽Spampcin 56-86的抗细菌和抗霉菌活性
Figure PCTCN2022100406-appb-000002
Figure PCTCN2022100406-appb-000003
注:MIC:最小抑菌浓度(μM),用a-b表示。a:肉眼可见菌体生长的最高蛋白浓度;b:肉眼未见菌体生长的最低蛋白浓度。
MBC:最小杀菌浓度(μM),用a-b表示。a:平板可见菌落生长的最高蛋白浓度;b:平板未见菌落生长的最低蛋白浓度。
实施例3 拟穴青蟹抗菌多肽Spampcin 56-86杀菌动力学曲线
选取金黄色葡萄球菌、铜绿假单胞菌、嗜水气单胞菌和大肠埃希氏菌作为待测菌,对拟穴青蟹抗菌多肽Spampcin 56-86的杀菌动力学进行测定。
具体方法如实施例2中所述的抗菌活性测定类似。调整拟穴青蟹抗菌多肽Spampcin 56-86终浓度至1倍MBC(金黄色葡萄球菌:6μM;铜绿假单胞菌:6μM;嗜水气单胞菌:12μM;大肠埃希氏菌:6μM;)。在共孵后2min、8min、10min、20min、25min、30min,将96孔细胞培养板取空白对照组、阴性对照组、待测实验组混匀,吸取6μL金黄色葡萄球菌菌悬液稀释至600μLDPBS中,混匀后吸取20μL涂布至营养肉汤平板上,37℃倒置培养1-2d,记录金黄色葡萄球菌单克隆数量,计算杀菌指数。在共孵后2min、4min、5min、10min、15min、20min、30min,将96孔细胞培养板取空白对照组、阴性对照组、待测实验组混匀,吸取6μL铜绿假单胞菌菌悬液稀释至600μLDPBS中,吸取40μL铜绿假单胞菌菌悬液涂布至营养肉汤平板上,37℃倒置培养1-2d,记录铜绿假单胞菌单克隆数量,计算杀菌指数。在共孵后10min、30min、60min、120min、150min,将96孔细胞培养板取空白对照组、阴性对照组、待测实验组混匀,吸取6μL嗜水气单胞菌菌悬液稀释至720μLDPBS中,吸取20μL嗜水气单胞菌 菌悬液涂布至营养肉汤平板上,28℃倒置培养1-2d,记录嗜水气单胞菌单克隆数量,计算杀菌指数。在共孵后10min、15min、20min、30min、60min,将96孔细胞培养板取空白对照组、阴性对照组、待测实验组混匀,吸取6μL大肠埃希氏菌菌悬液稀释至720μLDPBS中,吸取20μL大肠埃希氏菌菌悬液涂布至营养肉汤平板上,37℃倒置培养1-2d,记录大肠埃希氏菌单克隆数量,计算杀菌指数。杀菌指数是指经过一定时间共孵后,待测实验组的克隆数与阴性对照组克隆数的比值,用百分比表示,结果如图1所示。
实施例4 拟穴青蟹抗菌多肽Spampcin 56-86抗菌活性热稳定性
选取金黄色葡萄球菌和铜绿假单胞菌作为待测菌,对拟穴青蟹抗菌肽Spampcin 56-86的抗菌活性热稳定性进行测定。
具体方法如实施例2中所述的抗菌活性测定类似。调整拟穴青蟹抗菌肽Spampcin 56-86终浓度至1倍MBC(金黄色葡萄球菌:6μM,铜绿假单胞菌:6μM),分别在100℃沸水中水浴10min、20min、30min后置于冰上备用。将Spampcin 56-86与待测菌共同孵育,在0h、12h、24h、36h、48h时用酶标仪测定OD 600的值,结果如图2所示。
实施例5 拟穴青蟹抗菌多肽Spampcin 56-86作用后霉菌孢子萌发显微镜观察
选取尖孢镰孢、禾谷镰孢作为待测菌,观察拟穴青蟹抗菌肽Spampcin 56-86对霉菌孢子萌发的影响。
具体方法如实施例2中所述的抗菌活性测定类似。调整拟穴青蟹抗菌肽Spampcin 56-86蛋白浓度为6μM、12μM,置于冰上备用;调整各霉菌孢子最终浓度为5×10 4个/mL。将等体积各浓度Spampcin 56-86与各霉菌孢子于96孔细胞培养板混匀,置于28℃培养箱中,静置培养24h,在光学显微镜下观察霉菌孢子萌发情况,结果如图3和图4所示。
实施例6 拟穴青蟹抗菌多肽Spampcin 56-86与细菌作用后的扫描电镜观察
选取金黄色葡萄球菌、铜绿假单胞菌作为待测菌株,扫描电镜样品的制备按以下 步骤进行:
(1)如实施例2所述制备金黄色葡萄球菌、铜绿假单胞菌菌悬液(OD 600=0.4)冰上放置备用。
(2)用灭菌纯水溶解合成拟穴青蟹抗菌多肽Spampcin 56-86,并调整蛋白浓度为12μM,冰上放置备用。
(3)菌悬液和蛋白等体积混合后在适宜温度孵育适宜时间。其中金黄色葡萄球菌菌悬液与12μM拟穴青蟹抗菌多肽Spampcin 56-86于37℃孵育10min;铜绿假单胞菌菌悬液与12μM拟穴青蟹抗菌多肽Spampcin 56-86于37℃孵育30min。
(4)加入等体积戊二醛固定液,4℃固定2h后,1000g离心10min。
(5)去尽上清,PBS清洗一次,1000g离心10min。
(6)去除大部分上清,留约10μL液体,将剩余悬液滴在玻片上,4℃静置过夜。
(7)PBS清洗一次。
(8)30%-50%-70%-80%-90%-95%-100%-100%(v/v)乙醇逐级脱水,每级脱水15min。
(9)临界点干燥法干燥样品。
(10)喷金后用扫描电子显微镜观察及拍照,结果如图5和图6所示。
实施例7 拟穴青蟹抗菌多肽Spampcin 56-86细胞毒性测定
选取人肾上皮细胞(HEK-293T)和拟穴青蟹正常血细胞,对拟穴青蟹抗菌肽Spampcin 56-86细胞毒性进行测定。具体如下:
(1)收集生长状态良好的拟穴青蟹血细胞、人肾上皮细胞,调整细胞浓度为1×10 5个/mL,将细胞均匀吹散,在96孔细胞培养板中每孔加入100μL细胞悬液,置于适宜温度培养箱培养至80%以上细胞贴壁。
(2)小心吸出培养基,加入含有不同浓度(0μM、3μM、6μM、12μM、24μM、48μM)拟穴青蟹抗菌多肽Spampcin 56-86的培养基,置于适宜温度培养箱培养24h。
(3)加入20μLMTS-PMS溶液后避光孵育2h后,使用酶标仪测得OD 492值,评价拟穴青蟹抗菌多肽Spampcin 56-86的细胞毒性,结果如图7所示。
以上所述,仅为本发明的较佳实施例而已,故不能依此限定本发明实施的范围, 即依本发明专利范围及说明书内容所作的等效变化与修饰,皆应仍属本发明涵盖的范围内。
工业实用性
本发明公开了一种拟穴青蟹抗菌多肽Spampcin 56-86及其应用,其分子式为C 154H 256N 54O 33S 3,其氨基酸序列如SEQ ID NO:01所示。本发明的拟穴青蟹抗菌多肽Spampcin 56-86具有较强的抗细菌活性及抗霉菌活性,抗菌效果好,抗菌谱广,杀菌速率快,既可以研制成为抗细菌药物和抗霉菌药物,又可以应用于水产饲料添加剂,具有广泛的应用前景,具有工业实用性。

Claims (11)

  1. 拟穴青蟹抗菌多肽Spampcin 56-86,其特征在于:其分子式为C 154H 256N 54O 33S 3,其氨基酸序列如SEQ ID NO:01所示。
  2. 编码权利要求1所述拟穴青蟹抗菌肽Spampcin 56-86的核酸分子。
  3. 下述1)-4)中的任一种生物材料:
    1)含有权利要求2所述核酸分子的表达盒;
    2)含有权利要求2所述核酸分子的重组载体;
    3)含有权利要求2所述核酸分子的重组菌或转基因细胞系;
    4)含有所述重组载体的纳米颗粒。
  4. 如权利要求1所述的拟穴青蟹抗菌多肽Spampcin 56-86在制备抗细菌药物中的用途。
  5. 如权利要求4所述的拟穴青蟹抗菌多肽Spampcin 56-86,其特征在于:该抗细菌药物对金黄色葡萄球菌及其耐药菌、李斯特菌、粪肠球菌、屎肠球菌、表皮葡萄球菌、铜绿假单胞菌、鲍曼不动杆菌及其耐药菌、温和气单胞菌、嗜水气单胞菌、大肠埃希氏菌及其耐药菌、迟缓爱德华氏菌和荧光假单胞菌具有抑制和杀灭作用。
  6. 如权利要求1所述的拟穴青蟹抗菌多肽Spampcin 56-86在制备防霉菌药物中的用途。
  7. 如权利要求6所述的拟穴青蟹抗菌多肽Spampcin 56-86,其特征在于:该防霉菌药物对尖孢镰孢菌、禾谷镰孢菌和腐皮镰孢菌具有抑制和杀灭作用。
  8. 如权利要求1所述的拟穴青蟹抗菌多肽Spampcin 56-86在制备水产饲料添加剂中的应用。
  9. 一种抗细菌药物,其特征在于:其有效成分包括拟穴青蟹抗菌多肽Spampcin 56-86,其氨基酸序列如SEQ ID NO:01所示。
  10. 一种防霉菌药物,其特征在于:其有效成分包括拟穴青蟹抗菌多肽Spampcin 56-86,其氨基酸序列如SEQ ID NO:01所示。
  11. 一种水产饲料添加剂,其特征在于:其有效成分包括拟穴青蟹抗菌多肽Spampcin 56-86,其氨基酸序列如SEQ ID NO:01所示。
PCT/CN2022/100406 2021-06-25 2022-06-22 拟穴青蟹抗菌多肽Spampcin 56-86及其应用 WO2022268115A1 (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US18/454,855 US20230404076A1 (en) 2021-06-25 2023-08-24 Antimicrobial peptide spampcin56-86 from scylla paramamosain and applications thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202110716770.6A CN113307855B (zh) 2021-06-25 2021-06-25 拟穴青蟹抗菌多肽Spampcin56-86及其应用
CN202110716770.6 2021-06-25

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US18/454,855 Continuation US20230404076A1 (en) 2021-06-25 2023-08-24 Antimicrobial peptide spampcin56-86 from scylla paramamosain and applications thereof

Publications (1)

Publication Number Publication Date
WO2022268115A1 true WO2022268115A1 (zh) 2022-12-29

Family

ID=77380546

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/100406 WO2022268115A1 (zh) 2021-06-25 2022-06-22 拟穴青蟹抗菌多肽Spampcin 56-86及其应用

Country Status (3)

Country Link
US (1) US20230404076A1 (zh)
CN (1) CN113307855B (zh)
WO (1) WO2022268115A1 (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113307855B (zh) * 2021-06-25 2023-08-01 厦门大学 拟穴青蟹抗菌多肽Spampcin56-86及其应用
CN113999296B (zh) * 2021-11-04 2022-11-01 厦门大学 一种拟穴青蟹新型抗菌多肽Spgillcin177-189及其应用
CN114014910B (zh) * 2021-11-18 2022-12-09 厦门大学 一种拟穴青蟹抗真菌多肽Spamptin72-91及其应用
CN114773436B (zh) * 2022-04-27 2023-01-03 厦门大学 一种拟穴青蟹抗菌多肽SpRR20及其应用
CN114957430B (zh) * 2022-06-09 2023-12-12 厦门大学 一种拟穴青蟹抗菌多肽Sparepcin173-194及其应用
CN115246876B (zh) * 2022-06-09 2024-06-18 厦门大学 一种拟穴青蟹抗菌多肽Scyrepsin34-55及其应用
CN114957429B (zh) * 2022-06-09 2023-11-21 厦门大学 一种青蟹广谱抗菌多肽Scyrephemin60-81及其应用
CN116143883A (zh) * 2022-10-19 2023-05-23 厦门大学 一种广谱抗微生物肽Scymicrosin7-26及其应用

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000018798A1 (en) * 1998-09-25 2000-04-06 Xoma Technology Ltd. Antifungal and antibacterial peptide
CN102167736A (zh) * 2011-05-17 2011-08-31 厦门大学 一种拟穴青蟹抗菌肽Sphistin及其应用
CN103789317A (zh) * 2014-01-08 2014-05-14 广西壮族自治区海洋研究所 拟穴青蟹抗菌肽hyastatin基因克隆及编码蛋白重组和用途
US20150104492A1 (en) * 2013-10-14 2015-04-16 Alison McDermott Esculentin 1a Derivatives and Uses Thereof
CN105274134A (zh) * 2015-11-25 2016-01-27 厦门大学 拟穴青蟹抗菌肽scy2的制备方法与应用
CN110028568A (zh) * 2019-03-11 2019-07-19 厦门大学 一种拟穴青蟹抗菌多肽Sp-NPFin及其应用
CN111051335A (zh) * 2018-06-20 2020-04-21 厦门大学 一种拟穴青蟹抗菌肽Sparamosin及其应用
CN112159460A (zh) * 2020-09-29 2021-01-01 厦门大学 一种拟穴青蟹抗菌肽Spamprin4-23及其应用
CN112724221A (zh) * 2021-01-26 2021-04-30 厦门大学 拟穴青蟹抗菌肽Spamplin58-82及其应用
CN113307855A (zh) * 2021-06-25 2021-08-27 厦门大学 拟穴青蟹抗菌多肽Spampcin56-86及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1617881C2 (de) * 1965-10-13 1984-07-05 Takeda Chemical Industries, Ltd., Osaka Antibiotikum Enduracidin und seine Herstellung
CN104974228B (zh) * 2015-06-15 2017-10-17 四川合泰新光生物科技有限公司 一种小分子多肽zy4及其应用
WO2021134512A1 (zh) * 2019-12-31 2021-07-08 厦门大学 一种拟穴青蟹抗菌肽Scyreprocin新功能及其应用
KR102146779B1 (ko) * 2020-03-20 2020-08-24 유피씨(주) 항균소취조성물과 이의 제조방법 및 이를 이용한 통기성 폴리에틸렌 합지원단으로 제조한 방호복

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000018798A1 (en) * 1998-09-25 2000-04-06 Xoma Technology Ltd. Antifungal and antibacterial peptide
CN102167736A (zh) * 2011-05-17 2011-08-31 厦门大学 一种拟穴青蟹抗菌肽Sphistin及其应用
US20150104492A1 (en) * 2013-10-14 2015-04-16 Alison McDermott Esculentin 1a Derivatives and Uses Thereof
CN103789317A (zh) * 2014-01-08 2014-05-14 广西壮族自治区海洋研究所 拟穴青蟹抗菌肽hyastatin基因克隆及编码蛋白重组和用途
CN105274134A (zh) * 2015-11-25 2016-01-27 厦门大学 拟穴青蟹抗菌肽scy2的制备方法与应用
CN111051335A (zh) * 2018-06-20 2020-04-21 厦门大学 一种拟穴青蟹抗菌肽Sparamosin及其应用
CN110028568A (zh) * 2019-03-11 2019-07-19 厦门大学 一种拟穴青蟹抗菌多肽Sp-NPFin及其应用
CN112159460A (zh) * 2020-09-29 2021-01-01 厦门大学 一种拟穴青蟹抗菌肽Spamprin4-23及其应用
CN112724221A (zh) * 2021-01-26 2021-04-30 厦门大学 拟穴青蟹抗菌肽Spamplin58-82及其应用
CN113307855A (zh) * 2021-06-25 2021-08-27 厦门大学 拟穴青蟹抗菌多肽Spampcin56-86及其应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HU FENGXIAO, WU MIAOMIAO;ZHANG WEINI: "Research Advances on Antimicrobial Peptides in Aquatic Animals", FISHERIES SCIENCE, EL SALVADOR, vol. 38, no. 6, 1 November 2018 (2018-11-01), El Salvador, pages 1 - 7, XP093017280 *
IMJONGJIRAK CHANPRAPA; AMPHAIPHAN PAWANRAT; CHAROENSAPSRI WALAIPORN; AMPARYUP PITI: "Characterization and antimicrobial evaluation ofSpPR-AMP1, a proline-rich antimicrobial peptide from the mud crabScylla paramamosain", DEVELOPMENTAL AND COMPARATIVE IMMUNOLOGY, PERGAMON PRESS., US, vol. 74, 4 May 2017 (2017-05-04), US , pages 209 - 216, XP085046893, ISSN: 0145-305X, DOI: 10.1016/j.dci.2017.05.003 *
WANG KEJIAN, CHEN FANGYI; PENG HUI: "Progress in the discovery,study and application of new antimicrobial peptides fromScylla paramamosain", JOURNAL OF XIAMEN UNIVERSITY (NATURAL SCIENCE), vol. 60, no. 2, 1 March 2021 (2021-03-01), pages 1 - 10, XP093017265 *

Also Published As

Publication number Publication date
CN113307855A (zh) 2021-08-27
US20230404076A1 (en) 2023-12-21
CN113307855B (zh) 2023-08-01

Similar Documents

Publication Publication Date Title
WO2022268115A1 (zh) 拟穴青蟹抗菌多肽Spampcin 56-86及其应用
CN112159460B (zh) 一种拟穴青蟹抗菌肽Spamprin4-23及其应用
JP4310107B2 (ja) 生物活性を有する短ペプチド及び該ペプチドの使用方法
WO2019241938A1 (zh) 一种拟穴青蟹抗菌肽Sparamosin及其应用
CN110028568B (zh) 一种拟穴青蟹抗菌多肽Sp-NPFin及其应用
CN114014923B (zh) 拟穴青蟹抗菌多肽Sp-LECin及其应用
CN112724221B (zh) 拟穴青蟹抗菌肽Spamplin58-82及其应用
Grafskaia et al. Medicinal leech antimicrobial peptides lacking toxicity represent a promising alternative strategy to combat antibiotic-resistant pathogens
CN113121666B (zh) 抗菌肽Scybaumancin105-127及其应用
WO2023274024A1 (zh) 一种抗菌肽Scyampcin 44-63及其应用
WO2021068531A1 (zh) 一种黑鲷抗菌肽AS-hepc3 (48-56)及其应用
CN104592360A (zh) 碱性抗菌肽及其靶向设计和应用
CN110498848B (zh) 一种蜂毒肽变体及其应用
CN113583103B (zh) 一种抗菌肽HeHampⅠ(67-92)及其应用
WO2024093752A1 (zh) 一种新型抗菌肽及其药物组合物
CN113698464B (zh) 一种抗菌肽HeHampⅡ-4(63-88)及其应用
CN113527458B (zh) 一种抗菌肽HeHampⅡ-2(63-86)及其应用
CN112409457B (zh) 一类抗细菌多肽及其应用
CN110551191B (zh) 一种低溶血活性的蜂毒肽及其应用
CN114773436B (zh) 一种拟穴青蟹抗菌多肽SpRR20及其应用
CN113045629B (zh) 抗菌肽BIMix及其应用
CN114014910B (zh) 一种拟穴青蟹抗真菌多肽Spamptin72-91及其应用
CN116041468A (zh) 一种青环海蛇抗菌肽Hydrostatin-AMP3及其编码基因和应用
CN117126246A (zh) 一种大弹涂鱼抗菌多肽Bolespleenin及其应用
CN117264040A (zh) 一种拟穴青蟹新型抗菌肽Scyreptin及其应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22827607

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22827607

Country of ref document: EP

Kind code of ref document: A1